Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Blood (2024) 144 (18): 1924–1935.

https://doi.org/10.1182/blood.2024024631

Published: 2024

Includes: Supplemental data

Journal Articles

Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE

Blood blood.2024024667.

https://doi.org/10.1182/blood.2024024667

Published: 2024

Includes: Supplemental data

Journal Articles

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Blood (2024) 144 (3): 272–282.

https://doi.org/10.1182/blood.2023022730

Published: 2024

Includes: Supplemental data

Journal Articles

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Blood (2024) 143 (25): 2588–2598.

https://doi.org/10.1182/blood.2023022564

Published: 2024

Includes: Supplemental data

Journal Articles

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

Blood (2023) 142 (11): 961–972.

https://doi.org/10.1182/blood.2023020013

Published: 2023

Includes: Supplemental data

Journal Articles

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Julie Dubois, Julia von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar da Cunha-Bang, Christof Schneider, Christian Bjoern Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Nösslinger, Michael Baumann, Holger Hebart, Tobias Gaska, Josien C. Regelink, Ellen C. Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marcel Spaargaren, Eric Eldering, Stephan Stilgenbauer, Carsten U. Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater

Blood (2023) 142 (5): 446–459.

https://doi.org/10.1182/blood.2023019634

Published: 2023

Includes: Supplemental data

Journal Articles

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

Blood (2022) 140 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2022-171538

Published: 2022

Journal Articles

Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Andrea Visentin, Lydia Scarfò, Thomas Chatzikonstantinou, Anargyros Kapetanakis, Christos Demosthenous, Georgios Karakatsoulis, Martin Andres, Darko Antic, David Allsup, Mónica Baile, Dominique Bron, Antonella Capasso, Mark Catherwood, Rosa Collado, Raul Cordoba, Carolina Cuéllar-García, Julio Delgado, Maria Dimou, Michael Doubek, Lorenzo De Paoli, Maria Rosaria De Paolis, Giovanni Del Poeta, Maria Efstathopoulou, El-Ashwah Shimaa, Alicia Enrico, Lucia Farina, Angela Ferrari, Myriam Foglietta, Moritz Furstenau, Jose A. Garcia-Marco, Massimo Gentile, Eva Gimeno, Gomes da Silva Maria, Odit Gutwein, Yervand Hakobyan, Yair Herishanu, jose Angel Hernandez, Tobias Herold, Sunil Iyengar, Gilad Itchaki, Ozren Jaksic, Ann Janssens, Olga Kalashnikova, Elzbieta Kalicinska, Arnon P. Kater, Sabina Kersting, Jorge Labrador, Deepesh Lad, Luca Laurenti, Mark-David Levin, Enrico Lista, Lara Malerba, Roberto Marasca, Monia Marchetti, Juan Marquet Palomanes, Mattias Mattsson, Francesca Romana Mauro, Carlota Mayor-Bastida, Marta Morawska, Marina Motta, Talha Munir, Roberta Murru, Ivana Milosevic, Fatima Miras Calvo, Carsten Utoft Niemann, Jacopo Olivieri, Lorella Orsucci, Maria Papaioannou, Miguel Arturo Pavlovsky, Inga S. Piskunova, Barbara Pocali, Viola Maria Popov, Francesca Maria Quaglia, Giulia Quaresmini, Doreen te Raa, Gianluigi Reda, Gian Matteo Rigolin, Rosa Ruchlemer, Amit Shrestha, Martin Šimkovič, Martin Špaček, Paolo Sportoletti, Oana Stanca Ciocan, Tamar Tadmor, Elisabeth Vandenberghe, Marzia Varettoni, Candida Vitale, Ellen Van Der Spek, Michel Van Gelder, Ewa Wasik-Szczepanek, Lucrecia Yáñez, Mohamed A Yassin, Marta Coscia, Barbara Eichhorst, Alessandro Rambaldi, Niki Stavroyianni, Livio Trentin, Kostas Stamatopoulos, Paolo Ghia

Blood (2022) 140 (Supplement 1): 2333–2337.

https://doi.org/10.1182/blood-2022-163259

Published: 2022

Journal Articles

Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry

Blood (2022) 140 (Supplement 1): 9879–9881.

https://doi.org/10.1182/blood-2022-169956

Published: 2022

Journal Articles

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Blood (2022) 140 (Supplement 1): 842–845.

https://doi.org/10.1182/blood-2022-164786

Published: 2022

Journal Articles

Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

Blood (2022) 140 (Supplement 1): 839–841.

https://doi.org/10.1182/blood-2022-163775

Published: 2022

Journal Articles

Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/ TP53 Mutation

Blood (2022) 140 (Supplement 1): 834–836.

https://doi.org/10.1182/blood-2022-163245

Published: 2022

Journal Articles

Long-Term Host Immune Changes Following Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia

Arnon P. Kater, Barbara Eichhorst, Carolyn Owen, Ulrich Jaeger, Brenda Chyla, Marcus Lefebure, Rosemary Millen, Yanwen Jiang, Maria Thadani-Mulero, John F. Seymour

Blood (2022) 140 (Supplement 1): 7010–7012.

https://doi.org/10.1182/blood-2022-158275

Published: 2022

Journal Articles

Ibrutinib frontline in young patients with CLL

Barbara Eichhorst

Blood (2022) 140 (2): 80–81.

https://doi.org/10.1182/blood.2022016535

Published: 2022

Journal Articles

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

Blood (2022) 139 (9): 1318–1329.

https://doi.org/10.1182/blood.2021013208

Published: 2022

Includes: Supplemental data

Journal Articles

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

Blood (2022) 139 (2): 177–187.

https://doi.org/10.1182/blood.2021010845

Published: 2022

Includes: Supplemental data

Journal Articles

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations

Paula Cramer, Eugen Tausch, Julia von Tresckow, Adam Giza, Sandra Robrecht, Christof Schneider, Moritz Fürstenau, Petra Langerbeins, Othman Al-Sawaf, Benedikt W. Pelzer, Anna Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Barbara Eichhorst, Michael Kneba, Stephan Stilgenbauer, Michael Hallek

Blood (2021) 138 (19): 1805–1816.

https://doi.org/10.1182/blood.2020010484

Published: 2021

Includes: Supplemental data

Journal Articles

High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 72.

https://doi.org/10.1182/blood-2021-147729

Published: 2021

Journal Articles

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 71.

https://doi.org/10.1182/blood-2021-146161

Published: 2021

Journal Articles

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 2639.

https://doi.org/10.1182/blood-2021-147790

Published: 2021

NARROW

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/ TP53 Mutation

Long-Term Host Immune Changes Following Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia

Ibrutinib frontline in young patients with CLL

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations

High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only